| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/27/2001 | EP1109911A2 Staphylococcus aureus genes and polypeptides |
| 06/27/2001 | EP1109908A2 Leptin induced genes |
| 06/27/2001 | EP1109906A1 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus |
| 06/27/2001 | EP1109901A2 GABA B RECEPTOR SUBTYPES GABA B-R1c AND GABA B-R2 AND HETERODIMERS THEREOF |
| 06/27/2001 | EP1109900A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 06/27/2001 | EP1109893A2 Papillomaviruses, means for the detection thereof and therapy for diseases caused thereby |
| 06/27/2001 | EP1109833A2 Compositions and methods for the treatment of tumors |
| 06/27/2001 | EP1109828A1 Peptide fragments of cholera toxin b or enterotoxin b as vaccine adjuvants |
| 06/27/2001 | EP1109817A1 Phosphohalohydrins, method for making same and uses |
| 06/27/2001 | EP1109579A1 Use of tgf-beta inhibitors for treating cerebral disorders |
| 06/27/2001 | EP1109578A1 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
| 06/27/2001 | EP1109577A1 Multicomponent vaccines |
| 06/27/2001 | EP1109576A2 Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide |
| 06/27/2001 | EP1109575A2 Live virus vaccines to protect primates from hiv-1 infection and disease |
| 06/27/2001 | EP1109574A1 Vaccine against sexually transmitted diseases |
| 06/27/2001 | EP1109571A2 Methods of treating hypertension and compositions for use therein |
| 06/27/2001 | EP1109570A2 Method of modulating memory effector t-cells and compositions |
| 06/27/2001 | EP1109568A1 An antigenic peptide encoded by an alternative open reading frame of human macrophage colony-stimulating factor |
| 06/27/2001 | EP1109547A1 New use of taxoid derivatives |
| 06/27/2001 | EP1109539A1 Nanogel networks and biological agent composition thereof |
| 06/27/2001 | EP1109506A1 Improved method for targeted topical treatment of disease |
| 06/27/2001 | EP1109454A2 Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof |
| 06/27/2001 | EP0831896B1 In ovo vaccination against coccidiosis |
| 06/27/2001 | EP0629131B1 Antigens protective against (echinococcus granulosus) infection and vaccines containing such antigens |
| 06/27/2001 | EP0577648B1 Novel protein polycation conjugates |
| 06/27/2001 | CN1301301A I (vibrio cholerae) vaccine candidates and method of their constructing |
| 06/27/2001 | CN1301297A Medium and method for viral propagation and growth |
| 06/27/2001 | CN1301271A Methods for identifying inducers and inhibitors of propteolytic antibodies, compositions and their uses |
| 06/27/2001 | CN1301180A Recombinant i(mycoplasma hyopneumoniae) vaccine |
| 06/27/2001 | CN1301176A Use of active P40 conjugates for nasal delivery |
| 06/27/2001 | CN1301175A Humanized antibodies that recognize verotoxin II and cell line producing same |
| 06/27/2001 | CN1301174A Method of inducing an anti-tumor response against a lung metastasis in a melanoma patient |
| 06/27/2001 | CN1300850A Process for preparing VP2 protein from master host protective antigen (VP2) gene of infections burse disease virus (IBDV) and its gene engineering |
| 06/27/2001 | CN1300771A Hepatitis E virus gene sequence and its application |
| 06/27/2001 | CN1067722C Adenoviral vectors |
| 06/27/2001 | CN1067721C Hepatitis B surface antigen containing front surface antigen 1 and 2. immunodeterminant |
| 06/26/2001 | US6252055 Generating immunoglobulins; filter immunoglobulin solution through membrane, cycle filtrate through membrane, recover immunoglobulin |
| 06/26/2001 | US6252052 Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies |
| 06/26/2001 | US6252051 ErbB4 receptor-specific neuregulin related ligand antibodies and uses therefor |
| 06/26/2001 | US6252044 Riboflavin synthase polypeptide; for the controlled biosynthesis of riboflavin; for screening bactericides; for prevention of infection |
| 06/26/2001 | US6252043 Fusion protein for the treatment of inflammation; for the detection and prevention of leukocyte adhesion to endothelial cells |
| 06/26/2001 | US6251957 Preventing neutralizing antibodies; gene therapy |
| 06/26/2001 | US6251867 Antiangiogenic peptides and methods for inhibiting angiogenesis |
| 06/26/2001 | US6251864 Peptides and compounds that bind to a receptor |
| 06/26/2001 | US6251678 Mixture of virus particles, salt, histidine buffer and nonionic surfactant |
| 06/26/2001 | US6251663 Recombinant eukaryotic plasmids containing allergen-gene and use thereof for the prevention and/or treatment of allergic diseases |
| 06/26/2001 | US6251654 Modified small RNA viruses |
| 06/26/2001 | US6251652 Amino acid sequence from staphylococcus cystathionine gamma-lyase gene; drug screening; bactericides; bacteriostats; vaccines; antibodies |
| 06/26/2001 | US6251640 Genetically engineered virus having tata element promoter, tet operator sequence, and a gene which inhibits replication of virus when expressed; gene therapy; vaccines; viricides |
| 06/26/2001 | US6251634 Recombinant dna encoding gp63 glycoprotein of defined amino acid sequence; recombinant culture production; vaccines |
| 06/26/2001 | US6251631 Nucleotide sequence coding for ammonia dependent nicotinamide-adenine dinucleotide synthetase; probes for detection of infections |
| 06/26/2001 | US6251630 Polynucleotide encoding member of ribonuclease family of defined amino acid sequence; diagnosis; bacteriostats; bactericides; vaccines; treatment of otitis media, pneumonia, conjunctivitis, bacteremia, meningitis, sinusitis, and others |
| 06/26/2001 | US6251613 Method for detecting anti-GADII antibody and method for diagnosing cancer using said detection method |
| 06/26/2001 | US6251603 Evaluating cancer in humans; detect preferential gene expression in tumor, mix sample with antibodies which bind preferential protein, count amount of protein, an amplified protein value indicates adjustment in cancer classification |
| 06/26/2001 | US6251419 Membrane system for controlled tissue regeneration in cases of diseases of the periodontium |
| 06/26/2001 | US6251407 And adjuvant selected from manganese gluconate, calcium gluconate, zinc gluconate, calcium fructoheptonate, zinc glucoheptonate, or calcium glycerophosphate and an oily phase ester of ethoxylated fatty acids; immunostimulatory |
| 06/26/2001 | US6251406 Attenuated microorganism strains and their uses |
| 06/26/2001 | US6251405 Comprising borrelia burgdorferi outer surface protein (osp)c antigen and a second antigenic lipoprotein such as recombinant ospa, or streptococcus pneumoniae cell surface protein (pspa), both in same physio-chemical form |
| 06/26/2001 | US6251404 Collecting a sample of a naturally occurring isolated virus such as the iowa strain, and a naturally occuring strain that causes lesions in colostrum deprived piglets, treating to deactivate virus and admixing with carrier |
| 06/26/2001 | US6251403 Comprising a foreign dna encoding a cytokine inserted into a swinepox virus genome within a nonessential region and expressed in a host cell into which the virus is introduced; swinepox virus as a vector for delivery of vaccine antigens |
| 06/26/2001 | US6251401 Comprising haemophilus influenzae type b and neisseria meningitidis serotype c capsular oligosaccharide conjugates, where the oligosaccharides are size-selected to exclude short chain oligosaccharides |
| 06/26/2001 | US6251399 Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| 06/26/2001 | US6251397 Purified polypeptides encoded by open reading frames (orf's) of a highly virulent strain of the virus as determined by its ability to induce lung lesions in 51.9% of colostrum-deprived piglets; vaccines |
| 06/26/2001 | US6251394 Method and a system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion, and the use of said agents for said purpose |
| 06/26/2001 | US6251393 Conformation-specific anti-von Willebrand Factor antibodies |
| 06/26/2001 | US6251389 Human nucleotide pyrophosphohydrolase-2 |
| 06/26/2001 | US6251387 Topoisomerase I |
| 06/26/2001 | US6251385 Antigen stimulated cells for cancer treatment, free of bodily fluids |
| 06/26/2001 | CA1341263C Recombinant fowlpox virus, heterologous protein expression vectors, and fowl vaccines derived from this virus |
| 06/22/2001 | CA2328356A1 Recreational vehicles |
| 06/21/2001 | WO2001044816A2 Conformational and topological protein regulation |
| 06/21/2001 | WO2001044808A2 Methods of diagnosis and treatment by binding p75/airm1 |
| 06/21/2001 | WO2001044477A1 Method of enhancing immune responses to herpes simplex virus vaccine |
| 06/21/2001 | WO2001044473A2 Polypeptides and nucleic acids encoding same |
| 06/21/2001 | WO2001044472A1 Tnfr/opg-like molecules and uses thereof |
| 06/21/2001 | WO2001044445A2 Human lyases and associated proteins |
| 06/21/2001 | WO2001044441A1 Stabilizing diluent for polypeptides and antigens |
| 06/21/2001 | WO2001044300A2 Brain specific binding members |
| 06/21/2001 | WO2001044298A1 Improvement of therapeutic potential of immunoglobulin preparations |
| 06/21/2001 | WO2001044291A2 Polynucleotid encoding the rg1 polypeptide |
| 06/21/2001 | WO2001044289A2 Modified leukotoxin gene and protein |
| 06/21/2001 | WO2001044288A2 Toscana virus nucleoprotein |
| 06/21/2001 | WO2001044286A2 Five-helix protein |
| 06/21/2001 | WO2001044282A2 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 06/21/2001 | WO2001044278A2 Antigen preparations |
| 06/21/2001 | WO2001043774A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 06/21/2001 | WO2001043773A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 06/21/2001 | WO2001043772A2 Method and device for producing an autologous immunization vaccine against cancerous diseases (tumour vaccine) |
| 06/21/2001 | WO2001043771A1 Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory iga's |
| 06/21/2001 | WO2001043769A2 Antigen delivery |
| 06/21/2001 | WO2001043768A2 Vaccine composition comprising the toxoplasma protein sag3 |
| 06/21/2001 | WO2001043763A1 Betaglycan as an inhibin receptor and uses thereof |
| 06/21/2001 | WO2001043751A1 Novel helicobacter pylori-binding substances and use thereof |
| 06/21/2001 | WO2001043693A2 Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef |
| 06/21/2001 | WO2001019871A3 Delivery system for antidandruff agent |
| 06/21/2001 | WO2001014535A3 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β1,3-N-ACETYLGALACTOSAMINE-α-R/(GlcNAc to GalNAc) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3 |
| 06/21/2001 | WO2000078972A8 Regulation with binding cassette transporter protein abc1 |
| 06/21/2001 | WO2000055345A9 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 06/21/2001 | WO2000012128A9 Recombinant subunit vaccine against flaviviral infection |
| 06/21/2001 | WO1998010795A9 Tumor homing molecules, conjugates derived therefrom, and methods of using same |